Chicago Atlantic Group

https://chicagoatlantic.com

Chicago Atlantic Group is a private markets alternative investments manager and a credit-focused investment platform. The firm specializes in opportunistic lending, targeting markets characterized by structural inefficiencies and limited capital supply where risk is often mispriced. Its mission is to deliver attractive net risk-adjusted returns, consistent quarterly income, and long-term capital preservation. Headquartered in Chicago, Illinois, Chicago Atlantic also maintains offices in New York, Miami, and London.

Chicago Atlantic provides flexible debt solutions, including senior secured loans, asset-based lending, real estate loans, second-lien loans, lender finance, and project finance. A significant portion of its investment strategy focuses on providing capital to state-licensed cannabis operators in the U.S., an industry often underserved by traditional financing. The firm also serves growth and technology companies, specialized industries with limited access to conventional lending sources, and offers liquidity solutions. Chicago Atlantic is expanding its offerings into emerging markets private credit and operates a digital mining division for exposure to bitcoin.

Recent activities include the launch of a new Emerging Markets ABF Strategy in April 2026 and the closing of a net asset value-backed financing in the same month. The firm manages publicly traded entities, including Chicago Atlantic BDC, Inc. (NASDAQ: LIEN) and Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), both of which declared quarterly cash dividends in March 2026. Leadership includes Founding Partners Andreas Bodmeier, Tony Cappell, and John Mazarakis. Tony Cappell and Peter Sack serve as Co-CEOs of Chicago Atlantic Real Estate Finance, Inc., with Peter Sack also holding the CEO position for Chicago Atlantic BDC, Inc. Chicago Atlantic has closed over $3.3 billion in credit facilities since its inception, positioning itself as a prominent lender in its specialized market segments.

Latest updates

CID: 3374